IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 24.96

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-31 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.32 (+0.21%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In..

+0.19 (+0.26%)

USD 3.02B
FXH First Trust Health Care AlphaD..

+0.86 (+0.77%)

USD 1.26B
XHE SPDR® S&P Health Care Equipme..

+1.16 (+1.31%)

USD 0.22B
SBIO ALPS Medical Breakthroughs ETF

+1.20 (+3.25%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+1.71 (+1.78%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.32 (+1.10%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+1.33 (+2.12%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.96 (+3.42%)

USD 0.01B
IHF iShares U.S. Healthcare Provid..

+0.59 (+1.03%)

N/A

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.47% 57% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.47% 57% F 58% F
Trailing 12 Months  
Capital Gain 9.67% 62% D 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.67% 62% D 53% F
Trailing 5 Years  
Capital Gain -2.88% 48% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.88% 48% F 47% F
Average Annual (5 Year Horizon)  
Capital Gain -1.09% N/A N/A 32% F
Dividend Return -0.62% N/A N/A 22% F
Total Return 0.47% N/A N/A 11% F
Risk Return Profile  
Volatility (Standard Deviation) 36.65% N/A N/A 27% F
Risk Adjusted Return -1.68% N/A N/A 25% F
Market Capitalization 0.14B 60% D- 32% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike